The Patent Finder
HM

Hadasit Medical Research Services and Development Ltd.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Previously recorded as Immuron Limited (to 2020)

74 patents currently held

35 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
7 more records may belong here and await a decision; they are not counted.

The next term ends in Dec 2026. from the record

Of the 35 now held by other companies, 11 name Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. as their current owner, and 24 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
11
Ending by 2030
Dec 2026
Next term end
61
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Intracranial Volume Adaptor for Cerebral Blood Flow US 11,565,091
Cited by 10 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2039.
Ends Dec 2039 · High confidence
Also notable
Retinal Pigment Epithelial Cells Differentiated from Embryonic Stem Cells with Nicotinamide and Activin A US 8,956,866
The most cited patent in this portfolio, cited by 62 later US patents, top 10% of utility patents granted in 2015 in our data. Protection runs to 2029.
Ends Jun 2029 · High confidence
Also notable
Assay and Kit and Device for Removing Amylase from Body Fluids US 9,297,804
Granted 2016 and renewed at every maintenance window due so far. Protection runs to 2028.
Ends Nov 2028 · High confidence

Formerly held, still cited

Notable
Cited by 26 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2035.
Ends Apr 2035 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Dec 4 to 11, 2026 · next Dec 4
  • 3 fees due Jan 2 to 9, 2027 · next Jan 2
  • 2 fees due Feb 8 to 27, 2027 · next Feb 8
  • 1 fee due Mar 5, 2027
    The maintenance fee for Large Scale Production of Retinal Pigment Epithelial Cells (US 11,746,324) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
  • 3 fees due Apr 3 to 30, 2027 · next Apr 3
  • 2 fees due May 5 to 19, 2027 · next May 5
  • 3 fees due Jun 5 to 26, 2027 · next Jun 5
  • 3 fees due Jul 9 to 26, 2027 · next Jul 9
  • 1 fee due Sep 29, 2027
    The maintenance fee for Assay and Kit and Device for Removing Amylase from Body Fluids (US 9,297,804) comes due Sep 29, 2027. Unpaid by Mar 29, 2028, it lapses early.
  • 3 fees due Oct 5 to 14, 2027 · next Oct 5

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 23, 2026
  • 2 terms have ended since Aug 23, 2026

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 8,597,947Undifferentiated Stem Cell Culture Systems
In force
 · High confidence
In forceHigh confidence
US 8,535,645Antimicrobial Nanoparticulate Additives Forming Non-Leachable Sustained Antimicrobial Polymeric Compositions
In force
 · High confidence
In forceHigh confidence
US 9,297,804Assay and Kit and Device for Removing Amylase from Body Fluids
In force
 · High confidence
In forceHigh confidence
US 10,188,741Targeting of Innate Immune Response to Tumor Site
In force
 · High confidence
In forceHigh confidence
US 8,895,054Methods for Joint Lubrication and Cartilage Wear Prevention Making Use of Glycerophospholipids
In force
 · High confidence
In forceHigh confidence
US 8,956,866Retinal Pigment Epithelial Cells Differentiated from Embryonic Stem Cells with Nicotinamide and Activin A
In force
 · High confidence
In forceHigh confidence
US 8,735,149Motor Neurons Developed from Stem Cells
In force
 · High confidence
In forceHigh confidence
US 9,072,737tPA MUTANT IN THE TREATMENT OF ACUTE BRAIN INJURY AND NEURODEGENERATIVE DISORDERS
In force
 · High confidence
In forceHigh confidence
US 10,314,873Method of Treatment of Diseases Using Hoodia Extracts
In force
 · High confidence
In forceHigh confidence
US 10,117,930Anti-LPS Enriched Immunoglobulin Preparations For The Treatment And/Or Prophylaxis Of A Pathologic Disorder
In force
 · Medium confidence
In forceMedium confidence
10 of 74 patents shown.
Pro members see all 74.
Pro members: see all 74 patents
Also on record, not counted in the 74: 35 patents in force now held by others · 79 patents ended · 73 applications pending · 135 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited